IDEXX Laboratories, Inc. $IDXX Stock Position Reduced by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 38.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 106,831 shares of the company’s stock after selling 65,562 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in IDEXX Laboratories were worth $55,786,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in IDXX. SHP Wealth Management purchased a new position in IDEXX Laboratories in the 4th quarter valued at about $26,000. J.Safra Asset Management Corp acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $25,000. Elevation Wealth Partners LLC grew its holdings in shares of IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after buying an additional 32 shares in the last quarter. Pension & Wealth Management Advisors Inc. purchased a new stake in shares of IDEXX Laboratories during the third quarter worth about $29,000. Finally, Arlington Trust Co LLC grew its holdings in shares of IDEXX Laboratories by 46.3% during the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after buying an additional 19 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.79% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $566.76 on Friday. The business’s 50-day moving average price is $532.51 and its 200 day moving average price is $551.58. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $500.61 and a twelve month high of $769.98. The company has a market capitalization of $44.65 billion, a PE ratio of 39.86, a price-to-earnings-growth ratio of 2.96 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the previous year, the business earned $3.50 EPS. The firm’s revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on IDXX shares. Citigroup boosted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays decreased their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. The Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research note on Friday, October 16th. They issued a “buy” rating and a $740.00 target price for the company. UBS Group boosted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Seven investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $744.09.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.